| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.043 | 0.4 |